Neoadjuvant Docetaxel-Carboplatin-Trastuzumab Therapy in HER2-Positive Breast Cancer: A Single-Center Experience from Vietnam.

Cancer Manag Res · 2025 · PMC12410382 · PMID 40917758

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Other variables, including Stage III disease and decreased neutrophil count, did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.